Intensive insulin rx lowers glycemic variability in early DM

April 15, 2014
Intensive insulin rx lowers glycemic variability in early DM

(HealthDay)—Short-term intensive insulin therapy (IIT) can improve β-cell function in type 2 diabetes mellitus (T2DM) in association with decreased glycemic variability, according to a study published in the April issue of Diabetes Care.

Caroline K. Kramer, M.D., Ph.D., from Mount Sinai Hospital in Toronto, and colleagues examined whether β-cell functional recovery induced by short-term IIT correlated with glycemic variability. Sixty-one patients with T2DM (mean duration, three years) underwent four weeks of IIT. β- was assessed with the Insulin Secretion-Sensitivity Index-2 (ISSI-2) before and after IIT. Glucose variability was measured in the first and last week by the coefficient of variation of capillary glucose.

The researchers found that 55.7 percent of had a reduction in their glucose variability between the first and last week on IIT. There was a negative correlation between change in glucose variability and the change in β-cell function (P = 0.008). The only factor independently associated with the change in glucose variability was percentage change in ISSI-2 (P = 0.03). Patients with a 25 percent or higher increase in ISSI-2 had a reduction in glucose variability, compared with their peers who had virtually no change (−0.041 versus −0.0002; P = 0.006).

"It thus emerges that early in the course of T2DM, glucose variability is a modifiable parameter for which intervention may mitigate future risk of adverse outcomes," the authors write.

Two authors disclosed financial ties to Novo Nordisk, which funded the study.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Glycemic variability affects mood and quality of life

May 10, 2012

(HealthDay) -- Glycemic variability appears to be associated with lower quality of life and negative moods in women with type 2 diabetes, according to a study published in the March 30 issue of Diabetes Technology & Therapeutics.

Absolute incretin effect reduced in type 2 diabetes

June 25, 2012

(HealthDay) -- For patients with type 2 diabetes mellitus (T2DM) the absolute incretin effect is reduced compared with healthy individuals, but its relative importance is increased, particularly in first-phase insulin secretion, ...

Measures of glucose and its variability are inter-related

September 11, 2013

(HealthDay)—Hemoglobin A1c (HbA1c) and glycated albumin (GA) are inter-related and correlate with retinopathy and nephropathy, while only HbA1c correlates with cardiovascular disease, according to a study published online ...

Fat, protein impact postprandial glucose excursion in T1DM

December 19, 2013

(HealthDay)—For children with type 1 diabetes using intensive insulin therapy (IIT), high-fat (HF) and high-protein (HP) meals increase glucose excursions, with an additive effect observed, according to a study published ...

Recommended for you

Bacteria may cause type 2 diabetes

June 1, 2015

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers ...

'Crosstalk' gives clues to diabetes

June 15, 2015

Sometimes, listening in on a conversation can tell you a lot. For Mark Huising, an assistant professor in the Department of Neurobiology, Physiology and Behavior at the UC Davis College of Biological Sciences, that crosstalk ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.